ArticleAmerican journal of translational research2021
Effects of ticagrelor on proliferation, apoptosis, and inflammatory factors of human aortic vascular smooth muscle cells through lncRNA KCNQ1OT1.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Clinical value of long non-coding RNA KCNQ1OT1 in estimating the stenosis, lipid level, inflammation status, and prognostication in coronary heart disease patients.Journal of clinical laboratory analysis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was designed to determine the effects of ticagrelor on the proliferation and apoptosis of and inflammatory factors in human aortic vascular smooth muscle cells (HAVSMCs).
methodsA total of 20 patients who were first diagnosed with coronary heart disease (CHD) from August 2020 to March 2021 and 20 healthy adults were enrolled into the study. Oxidized low-density lipoprotein (ox-LDL) and different concentrations of ticagrelor were applied in the treatment of HAVSMCs, and then the cell proliferation and apoptosis and the expression of apoptosis-related proteins, inflammatory factors, and IκBα in them were determined.
resultsCompared with the ox-LDL group, the OD value was significantly increased after ticagrelor treatment, and the apoptosis rate was significantly reduced (P<0.05); compared with the ox-LDL group, the B lymphoma-2 (Bcl-2) protein, IκB, KCNQ1OT1 expression in the ticagrelor group increased significantly, Bcl-2-associated X protein (Bax), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) expression decreased significantly (P<0.05); The expression of serum KCNQ1OT1 in patients with coronary heart disease was significantly higher than that in healthy individuals (P<0.05).
conclusionTicagrelor may regulate the expression of lncRNA KCNQ1OT1 and up-regulate the expression of IκBα to promote proliferation and anti-apoptosis, so as to prevent ox-LDL from oxidative damage to HAVSMCs.
Indexed as
Identifiers
35035688PMC8748171W4206884348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.